Abstract
Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.
Keywords: Angiogenesis, bevacizumab, glioma, monoclonal antibodies, nimotuzumab, passive immunotherapy.
Current Cancer Therapy Reviews
Title:Trends in Malignant Glioma Monoclonal Antibody Therapy
Volume: 11 Issue: 2
Author(s): Ivan Chekhonin and Olga Gurina
Affiliation:
Keywords: Angiogenesis, bevacizumab, glioma, monoclonal antibodies, nimotuzumab, passive immunotherapy.
Abstract: Although new passive and active immunotherapy methods are emerging, unconjugated monoclonal antibodies remain the only kind of biological preparations approved for high-grade glioma therapy in clinical practice. In this review, we combine clinical and experimental data discussion. As antiangiogenic therapy is the standard of care for recurrent glioblastoma multiforme (GBM), we analyze major clinical trials and possible therapeutic combinations of bevacizumab, the most common monoclonal antibody to vascular endothelial growth factor (VEGF). Another humanized antibody to gain recognition in GBM is epidermal growth factor (EGFR) antagonist nimotuzumab. Other antigens (VEGF receptor, platelet-derived growth factor receptor, hepatocyte growth factor and c-Met system) showed significance in gliomas and were used to create monoclonal antibodies applied in different malignant tumors. We assess the role of genetic markers (isocitrate dehydrogenase, O6-methylguanine-DNA methyltransnsferase) in GBM treatment outcome prediction. Besides antibodies studied in clinical trials, we focus on perspective targets and briefly list other means of passive immunotherapy.
Export Options
About this article
Cite this article as:
Chekhonin Ivan and Gurina Olga, Trends in Malignant Glioma Monoclonal Antibody Therapy, Current Cancer Therapy Reviews 2015; 11 (2) . https://dx.doi.org/10.2174/1573394711888150917142941
DOI https://dx.doi.org/10.2174/1573394711888150917142941 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Integrative Systems Analysis of High-grade Glioma Cell Lines: TLRs, Wnt, BRCA1, Netrins, STXBP1 and MDH1 Provide Putative Molecular Targets for Therapeutic Intervention
Current Pharmacogenomics and Personalized Medicine Liposomes: An Emerging Approach for the Treatment of Cancer
Current Pharmaceutical Design Endothelial Cell Targeted Molecular Imaging in Tumor Angiogenesis: Strategies and Current Status
Current Pharmaceutical Biotechnology Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Targeted Delivery of Anti-Inflammatory Agents to Tumors
Current Pharmaceutical Design Role of Angiogenesis Inhibitors in Colorectal Cancer: Sensitive and Insensitive Tumors
Current Cancer Drug Targets Snake Venom L-Amino Acid Oxidases: Some Consideration About their Functional Characterization
Protein & Peptide Letters Gamma Linolenic Acid: An Antiinflammatory Omega-6 Fatty Acid
Current Pharmaceutical Biotechnology Strategies of overcoming the physiological barriers for tumor-targeted nano-sized drug delivery systems
Current Pharmaceutical Design Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Novel Agents in CNS Myeloma Treatment
Central Nervous System Agents in Medicinal Chemistry Editorial (Thematic Issue: PET/CT in External Beam Radiation Therapy Dose Planning)
Current Radiopharmaceuticals Systems Biology Approach for the Identification of Diagnostic and Therapeutic Targets in Medulloblastomas
Current Pharmacogenomics and Personalized Medicine Neuroprotective Effects of Citrus Fruit-Derived Flavonoids, Nobiletin and Tangeretin in Alzheimer's and Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Procyanidin B2 3,3″-di-O-gallate Inhibits Endothelial Cells Growth and Motility by Targeting VEGFR2 and Integrin Signaling Pathways
Current Cancer Drug Targets Dendritic Cell Immunotherapy for Melanoma
Reviews on Recent Clinical Trials The Role of Natural Products in the Discovery of New Drug Candidates for the Treatment of Neurodegenerative Disorders I: Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Stability Testing During Development of Nanopharmaceuticals
Pharmaceutical Nanotechnology Polyunsaturated Fatty Acids and their Metabolites in Neural Development and Implications for Psychiatric Disorders
Current Psychopharmacology RAGE as a Receptor of HMGB1 (Amphoterin): Roles in Health and Disease
Current Molecular Medicine